Trial Profile
A 2-Part, Non-randomized, Open-label Study to Evaluate the Effect of Itraconazole, Rifampicin, Rabeprazole, and Omeprazole on the Pharmacokinetics of Belumosudil (KD025)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 19 Jul 2022
Price :
$35
*
At a glance
- Drugs Belumosudil (Primary) ; Itraconazole; Omeprazole; Rabeprazole; Rifampicin
- Indications Autoimmune disorders; Graft-versus-host disease; Idiopathic pulmonary fibrosis; Plaque psoriasis; Systemic scleroderma
- Focus Pharmacokinetics
- Sponsors Kadmon Corporation
- 01 Jul 2022 Results published in the Clinical Pharmacology in Drug Development
- 12 Aug 2019 Status changed from recruiting to completed.
- 11 Oct 2018 Number of treatment arms has been increased hence number of patients has also increased. Endpoints has also added.